NSCLC Education Center Disease State Hub

Non-Small Cell Lung Cancer

Education Center

Recent News

FDA Approval

FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer

10/03/2024

Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...

Based on results from the...

10/03/2024

Oncology

News

Investigating Low-Dose Subcutaneous Decitabine Treatment for Patients With Myelofibrosis

10/02/2024

Amber Denham ;

According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...

According to a prospective phase...

10/02/2024

Oncology

News

Adjuvant Aspirin Shows Protective Effect Among Patients With PIK3CA-Mutant Colon Cancer

10/02/2024

Allison Casey ;

The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.

The phase 3 SAKK 41/13 trial...

10/02/2024

Oncology

News

Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS

10/02/2024

Amber Denham ;

Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.

Luspatercept provides a new...

10/02/2024

Oncology

Conference Coverage

Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer

10/01/2024

Stephanie Holland ;

According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...

According to interim analysis...

10/01/2024

Oncology

FDA Approval

FDA Approves Selpercatinib for Adult and Pediatric Patients With Advanced or Metastatic Medullary Thyroid Cancer

09/27/2024

Stephanie Holland ;

Based on results from the phase 3 LIBRETTO-531 study, the FDA has granted traditional approval to selpercatinib for adult and pediatric patients 2 years and older with advanced or metastatic medullary thyroid cancer harboring a RET mutation.

Based on results from the phase...

09/27/2024

Oncology

News

Odronextamab Demonstrates Durable Responses, Manageable Safety Among Patients With Heavily Pretreated R/R Follicular Lymphoma

09/26/2024

Amber Denham ;

According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.

According to results from a...

09/26/2024

Oncology

News

Belantamab Mafodotin Plus Pomalidomide-Dexamethasone Demonstrates Efficacy Among Patients With Triple Class Exposed/Refractory Multiple Myeloma

09/26/2024

Amber Denham ;

Patients with triple class exposed/refractory multiple myeloma treated with belantamab mafodotin plus pomalidomide-dexamethasone achieved high clinical response rates with durable remissions, determined a post-hoc analysis of the ALGONQUIN...

Patients with triple class...

09/26/2024

Oncology

News

FDA Approves Osimertinib Following Chemoradiation for Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer Harboring EGFR Mutations

09/25/2024

Stephanie Holland ;

Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...

Based on results from the LAURA...

09/25/2024

Oncology

Conference Coverage

Adagrasib Improves Response Among Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

09/25/2024

Stephanie Holland ;

According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...

According to exploratory results...

09/25/2024

Oncology